- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA approval August 2021)
- Why 4/10
- Skytrofa is already FDA-approved and commercially marketed with no pending regulatory decision. The next hard catalyst would be a potential FDA filing for adult GHD indication, but no submission date has been announced. As an approved drug with no imminent binary catalyst, the impact score is capped at 4 per the rubric.
Skytrofa is a steady commercial contributor but not the primary value driver for ASND anymore, YORVIPATH's rapid growth and the YUVIWEL launch are the main catalysts. Watch for any FDA filing for adult GHD indication (completed Phase 3 data in hand) and quarterly Skytrofa sales trajectory. The stock's next major binary catalyst is the EU MAA decision for YUVIWEL expected in Q4 2026.
Price Chart
Executive Summary
Lonapegsomatropin (brand name Skytrofa) is Ascendis Pharma's once-weekly prodrug of human growth hormone, approved by the FDA in August 2021 for pediatric growth hormone deficiency (GHD). It uses Ascendis's TransCon technology to enable weekly dosing versus daily injections with standard somatropin. Skytrofa generated €55M in Q2 2026 revenue (+105% YoY total product revenue), but it is now the #2 commercial product for ASND behind YORVIPATH (€252M). Phase 3 trials in adult GHD are completed, though no FDA filing for that indication has been announced. The drug faces competition from daily somatropin generics and other long-acting GH products. ASND is a multi-product commercial-stage biotech with strong analyst support (mean target $315, ~19% upside), but the stock's thesis is increasingly driven by YORVIPATH and the newly launched YUVIWEL rather than Skytrofa alone.
How It Works
Lonapegsomatropin is a long-acting prodrug of somatropin (human growth hormone). It uses Ascendis's TransCon technology to temporarily attach an inert carrier molecule to the growth hormone, allowing it to circulate in the body longer before being released. This enables once-weekly injections instead of the standard daily shots required by conventional growth hormone drugs, reducing the treatment burden for patients with growth hormone deficiency.
Trial Status
FDA-approved in August 2021 for pediatric growth hormone deficiency based on pivotal Phase 3 trials (NCT02781727, NCT03305016) showing non-inferior efficacy to daily somatropin. Two Phase 3 trials in adults with GHD (NCT04615273, NCT05171855) are completed with results available, but no FDA submission for adult indication has been announced as of mid-2026.
The Two-Sided Case
Upcoming Catalysts
- Potential FDA filing for adult GHD indication (Phase 3 data complete)
- Quarterly Skytrofa revenue reports as commercial adoption scales
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Ascendis Pharma Press Release ASND ·Originating report